Fig. 3

Baseline immune signatures between FL patients with or without progression disease (PD) (A) at baseline and (B) after 6-cycle treatment; Within-group and between-group comparisons of the changes of T-cell subsets (C) across treatment in PD/Non-PD group were performed using the Wilcoxon paired-sign rank test and the Wilcoxon rank sum test.